A 20-cent 'wonder drug' is being studied as a colon-cancer-fighting supplement, and it looks promising

A cheap, widely prescribed diabetes drug that some doctors have called a "wonder drug" may hold promise as a colon-cancer -fighting supplement.
Scientists who presented at the American Association for Cancer Research conference in Chicago last week are studying how metformin — the most popular diabetes medication worldwide — interacts with tough-to-treat colon cancer cells. Their research is still early and ongoing.
"Metformin seems like it could have a really interesting supplemental approach to therapy," Holli Loomans-Kropp, a gastrointestinal cancer prevention researcher at The Ohio State University, who is leading the ongoing study, told Business Insider. "We're opening up some doors to what this could do."
Previous research found that people taking metformin for diabetes have lower colon cancer rates, suggesting the drug may be doing something protective to help prevent cancer from developing. This new study is one of the first to look at whether metformin could actually fight colon cancer cells once the disease develops.
Based on what Loomans-Kropp and her team have seen so far in cell-culture dishes, metformin could become a helpful "supplement" to certain cancer treatment regimens in the future. It wouldn't be potent enough to treat cancer on its own, but could be used alongside other treatments.
Loomans-Kropp is especially excited about the drug's potential in treating a common type of colon cancer caused by a mutated KRAS gene, which tends to be very tough to treat. Her research is still in the early stages; further animal testing is required before human clinical trials can begin.
A drug that changes how the body uses energy
One of the big benefits Loomans-Kropp sees to studying metformin for colon cancer treatment is a practical one — it's a drug that's already widely accessible and affordable.
"I always like to ask the question: Are there medications or agents that we already know, that are already used, that we have safety/toxicity profiles for, that we can then repurpose for something else?"
Metformin has been studied and used by millions of patients worldwide. And as an off-patent, generic drug, it's cheap — it costs 10 to 20 cents per pill.
It's sometimes referred to as a " wonder drug" by doctors for its beneficial effects outside blood-sugar control. Scientists have studied it for heart health, cancer prevention, and dementia.
Metformin works for diabetes because it changes the way the body processes and produces sugar. Some scientists believe it may hold promise as an antiaging drug. Like exercise or fasting, metformin regulates how the body uses energy and encourages autophagy, a process that allows the body to process old and damaged cells. Loomans-Kropp hopes that metformin could also inhibit colon cancer cells from using energy to grow and develop.
"If metformin maybe can be used to redirect or change how the cell uses energy, which then ultimately changes how it divides and how it proliferates, this could be a mechanism to exploit," Loomans-Kropp said.
The same energy-shifting mechanism has longevity researchers excited about metformin as a tool for disease prevention.
Dr. Nir Barzilai, a leading longevity researcher who suspects metformin may be beneficial for healthy aging, said metformin may be a "suitable" option for cancer prevention. When it comes to fighting cancer, he agrees with Loomans-Kropp that more study is needed.
"Let the science lead," he told Business Insider in an email.
Loomans-Kropp is hoping that if these initial cancer cell results are successful, she can begin testing metformin as colon cancer treatment on animals within a year.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

4 hours ago

• Yahoo

Forget 'biological age' tests — longevity experts are using an $800 under-the-radar blood test to measure aging in real-time

Doctors and scientists are using a blood plasma test to study longevity. The test measures proteins and can tell you about your organ health. This field of proteomics could one day help detect diseases like cancer before they start. Should you have that second cup of coffee? How about a little wine with dinner? And, is yogurt really your superfood? Scientists are getting closer to offering consumers a blood test that could help people make daily decisions about how to eat, drink, and sleep that are more perfectly tailored to their unique biology. The forthcoming tests could also help shape what are arguably far more important health decisions, assessing whether your brain is aging too fast, if your kidneys are OK, or if that supplement or drug you're taking is actually doing any good. It's called an organ age test, more officially (and scientifically) known as "proteomics" — and it's the next hot "biological age" marker that researchers are arguing could be better than all the rest. "If I could just get one clock right now, I'd want to get that clock, and I'd like to see it clinically available in older adults," cardiologist Eric Topol, author of the recent bestseller "Super Agers: An Evidence-Based Approach to Longevity," told Business Insider. Topol said armed with organ age test results, people could become more proactive stewards of their own health, before it's too late. "When we have all these layers of data, it's a whole new day for preventing the disease," Topol said. "You see the relationship with women's hormones. You see the relationship with food and alcohol. You don't ever get that with genes." A test like this isn't available to consumers just yet, but it's already being used by researchers at elite universities and high-end longevity clinics. They hope it can become a tool any doctor could use to assess patient health in the next few years. A startup called Vero, which was spun out of some foundational proteomics research at Stanford University, is hoping to beta test a proteomics product for consumers this year. "Knowing your oldest organ isn't the point; changing the trajectory is," Vero co-founder and CEO Paul Coletta told a crowd gathered at the Near Future Summit in Malibu, California, last month. Coletta told Business Insider Vero's not interested in doing "wealthcare." The company plans to make its test available to consumers for around $200 a pop, at scale. Their draw only requires one vial of blood. The big promise of proteomics is that it could be a more precise real-time tool for tracking important but subtle changes that emerge inside each of us as we age. Genetic testing can measure how our bodies are built, spotting vulnerabilities in a person's DNA that might predispose them to health issues. Standard clinical measurements like a person's weight, blood pressure, or cholesterol readings are a useful proxy for potential health issues. Then there are the increasingly popular "biological age" tests available to consumers at home. Most of those look at "epigenetic changes" — how environmental factors affect our gene expression. Proteomics does something different and new. It measures the product that our bodies make based on all those genetic and environmental inputs: proteins. It offers a live assessment of how your body is running, not just how it's programmed. If validated in the next few years, these tests could become key in early disease detection and prevention. They could help influence all kinds of medical decisions, from big ones like "What drugs should I take?" to little ones like "How does my body respond to caffeine or alcohol?" Some high-end longevity clinics are already forging ahead using proteomics to guide clinical recommendations, albeit cautiously. Dr. Evelyne Bischof, a longevity physician who treats patients worldwide, said she uses proteomic information to guide some of the lifestyle interventions she recommends to her patients. She may suggest a more polyphenol-rich diet to someone who seems to have high inflammation and neuroinflammation based on proteomic test results, or may even suggest they do a little more cognitive training, based on what proteomics says about how their brain is aging. Dr. Andrea Maier, a professor of medicine and functional aging at the National University of Singapore, told BI she uses this measurement all the time in her longevity clinics. For her, it's just a research tool, but if the results of her ongoing studies are decent, she hopes to be able to use it clinically in a few years' time. "We want to know what kind of 'ageotype' a person is, so what type of aging personality are you, not from a mental perspective, but from a physical perspective," Maier said. "It's really discovery at this moment in time, and at the edge of being clinically meaningful." "Once we have that validated tool, we will just add it to our routine testing and we can just tick the box and say, 'I also want to know if this person is a cardiac ager, or a brain ager, or a muscle ager' because now we have a sensitive parameter — protein — which can be added," Maier said. The two big-name proteomics tests are Olink and SOMAscan. For now, their high-end screening costs around $400-$800 per patient. "I'm losing lots of money at the moment because of proteomics for clinical research!" Maier said. Top aging researchers at Stanford and Harvard are pushing the field forward, racing to publish more novel insights about the human proteome. The latest findings from Harvard aging researcher Vadim Gladyshev's lab, published earlier this year, suggest that as we age, each person may even stand to benefit from a slightly different antiaging grocery list. To research this idea, Gladyshev looked at proteins in the blood of more than 50,000 people in the UK, all participants in the UK Biobank who are being regularly tested and studied to learn more about their long-term health. He tracked their daily habits and self-reported routines like diet, occupation, and prescriptions, comparing those details to how each patient's organs were aging. He discovered some surprising connections. Yogurt eating, generally speaking, tended to be associated with better intestinal aging but had relatively no benefit to the arteries. White wine drinking, on the other hand, seemed to potentially confer some small benefit to the arteries while wreaking havoc on the gut. "The main point is that people age in different ways in different organs, and therefore we need to find personalized interventions that would fit that particular person," Gladyshev told BI. "Through measuring proteins, you assess the age of different organs and you say, 'OK, this person is old in this artery.'" For now, there's too much noise in the data to do more. Dr. Pal Pacher, a senior investigator at the National Institute on Alcohol Abuse and Alcoholism who studies organ aging and injuries, told BI that proteomics is simply not ready for clinical use yet. There's just too much noise in the data. But he imagines a future where a more sophisticated protein clock could help link up which people may be most vulnerable to diseases like early cancer, kidney disease, and more. (A California-based proteomics company called Seer announced last weekend that it is partnering with Korea University to study whether proteomics can help more quickly diagnose cancer in young people in their 20s and 30s.) "How beautiful could it be in the future?" Maier said. "Instead of three hours of clinical investigation, I would have a tool which guides me much, much better, with more validity towards interventions." Read the original article on Business Insider

Business Insider

a day ago

• Business Insider

Starship's 4th straight rocket explosion is the latest public setback for Musk's Mars dreams

SpaceX's flagship rockets keep blowing up. On Wednesday night, one of the Elon Musk-run space technology company's latest rockets erupted into an inferno on the launchpad. The explosion, which enveloped a portion of SpaceX's Starbase campus in Texas in fire and smoke, was meant to be a routine test ahead of a launch for the company's Starship program. The company plans to use Starship rockets — the successor to its Falcon models — to conduct missions to the moon, and eventually, Mars. Wednesday's explosion marks the fourth consecutive failure for SpaceX's Starship rockets this year. In May, a Starship rocket successfully made it through the Earth's atmosphere — but failed to release a payload of practice satellites into space and then spun out of control on its trip back to the planet. Starship rockets also exploded on two other trips this year. SpaceX has embraced its failures, using data collected from explosions and missteps to improve future products. Wednesday's explosion was intended to be a "static fire test," where the engines fire while the rocket is held on the launchpad with clamps, rather than launched into the atmosphere. Musk brushed off the mishap as "just a scratch." He said that preliminary data showed the failure was related to a container of pressurized nitrogen in the payload bay. "If further investigation confirms that this is what happened, it is the first time ever for this design," Musk wrote on X, formerly Twitter. A representative for SpaceX didn't immediately respond to Business Insider's request for comment. On X, the company said the test experienced "a major anomaly." It said all of the company's personnel were safe and accounted for. This year's string of failures marks a stark departure from last year, where the Starship program had better success, proving that its rockets could be reused and even land vertically after a trip to space. Although SpaceX is a private company, Musk had come under scrutiny from Tesla shareholders earlier this year over his role in President Donald Trump's administration. A number of major shareholders have complained that Musk had been spending less time operating the company while he oversaw the Department of Government Efficiency. SpaceX is heavily reliant on government contracts, and has one with NASA for the Starship to put astronauts on the moon by 2027, before Trump's term ends. Musk left the administration earlier this month and exchanged verbal volleys with Trump, accusing him without evidence of blocking the release of government documents related to the now-dead pedophile Jeffrey Epstein. The White House called Musk's comments "unfortunate." SpaceX typically conducts test launches frequently and has a high tolerance for failure, knowing the next test is just around the corner. The strategy has worked well for the company's Falcon rocket program, which in over a decade has launched hundreds of flights. On Monday, the company successfully launched a Falcon 9 rocket into space. The rocket sent more than two dozen Starlink satellites into orbit. "SpaceX's philosophy is 'fail fast, learn faster' and usually is undeterred by failures like this one," wrote space policy analyst Marcia Smith of the Starship explosion.

Medscape

2 days ago

• Medscape

ASCO 2025: Clinical Impact of New Data in Advanced NSCLC

Isabel Preeshagul, DO, comments on treatment updates in advanced non-small cell lung cancer shared at ASCO 2025, emphasizing their impact on patients. The KRYSTAL-7 study showed that adagrasib combined with pembrolizumab achieved a 43% response rate in KRAS G12C-mutant patients, especially those with PD-L1 over 50%, though liver toxicity was a key concern. The REZILIENT1 study highlighted zipalertinib's activity in EGFR exon 20 insertion–positive patients, with encouraging CNS responses and manageable side effects like paronychia. Lastly, the COCOON study showed that a proactive dermatologic regimen significantly reduced skin toxicities from amivantamab, though practical challenges remain in balancing effectiveness with patient burden.